Italian authorities fine drugmaker for ‘excessive’ pricing of rare disease drug

Antitrust regulators in Italy have fined a drugmaker practically $3.8 million for years of “extreme” value hikes on a uncommon illness medication, the newest occasion through which European authorities have cracked down on the pharmaceutical trade for harming shoppers and taxpayers.

At concern is a medication often known as CDCA that’s used to deal with folks with cerebrotendinous xanthomatosis, or CTX, a uncommon genetic metabolic illness. A model was accessible for many years at a low value. However the drug was purchased by Leadiant Biosciences which, by 2014, started elevating the value in a number of nations earlier than withdrawing the medication from the market fully the next yr.